Information Provided By: 
Fly News Breaks for January 4, 2016
RHHBY, PACB
Jan 4, 2016 | 07:39 EDT
Cantor Fitzgerald analyst Bryan Brokmeier raised his price target for Pacific Biosciences (PACB) to $18 citing the launch of Sequel and a potential buyout from Roche (RHHBY). Brokmeier calls the launch a "game changer" and views a Roche buyout as likely in the second half of 2016. The analyst sees an acquisition price for Pacific in the $18-$33 per share range. He keeps a Buy rating on the name.
News For PACB;RHHBY From the Last 2 Days
RHHBY
Apr 25, 2024 | 11:44 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
